Catalytically cleaves crosslinks between advanced glycation end products (AGE) and extracellular matrix proteins. Prepn: A. Cerami et al., EP 808163; eidem, US 5853703 (1997, 1998 both to Alteon; Picower Inst. Med. Res.). In vivo AGE cross-link breaking activity: B. H. R. Wolffenbuttel et al., Proc. Natl. Acad. Sci. USA 95, 4630 (1998). Clinical pharmacology and effect on vascular stiffening: D. A. Kass et al., Circulation 104, 1464 (2001); in elderly patients with heart failure: W. C. Little et al., J. Card. Fail. 11, 191 (2005). Review of pharmacology and therapeutic potential: S. Vasan et al., Arch. Biochem. Biophys. 419, 89-96 (2003); of clinical evaluations in cardiovascular disease: G. L. Bakris et al., Am. J. Hypertens. 17, 23S-30S (2004).
In treatment of cardiovascular complications of diabetes and aging.
Antiatherosclerotic